CETIRIZINE HYDROCHLORIDE HIVES Drug Patent Profile
When do Cetirizine Hydrochloride Hives patents expire, and when can generic versions of Cetirizine Hydrochloride Hives launch?
Cetirizine Hydrochloride Hives is a drug marketed by Aiping Pharm Inc, Dr Reddys Labs Ltd, Mylan, Orbion Pharms, Perrigo R And D, Pharmazone, Sun Pharm Inds Inc, Sun Pharm Inds Ltd, Unichem, Unique, Aurobindo Pharma Ltd, Bionpharma, Amneal Pharms Ny, Taro, and Torrent Pharms Llc. and is included in seventeen NDAs.
The generic ingredient in CETIRIZINE HYDROCHLORIDE HIVES is cetirizine hydrochloride. There is one drug master file entry for this compound. One hundred and sixty-two suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cetirizine Hydrochloride Hives
A generic version of CETIRIZINE HYDROCHLORIDE HIVES was approved as cetirizine hydrochloride by PADAGIS US on June 17th, 2008.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CETIRIZINE HYDROCHLORIDE HIVES?
- What are the global sales for CETIRIZINE HYDROCHLORIDE HIVES?
- What is Average Wholesale Price for CETIRIZINE HYDROCHLORIDE HIVES?
Summary for CETIRIZINE HYDROCHLORIDE HIVES
| US Patents: | 0 |
| Applicants: | 15 |
| NDAs: | 17 |
| Finished Product Suppliers / Packagers: | 72 |
| Raw Ingredient (Bulk) Api Vendors: | 109 |
| Clinical Trials: | 96 |
| Patent Applications: | 4,922 |
| DailyMed Link: | CETIRIZINE HYDROCHLORIDE HIVES at DailyMed |
Recent Clinical Trials for CETIRIZINE HYDROCHLORIDE HIVES
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | PHASE1 |
| University of Phayao | NA |
| Pengfei Qiu | NA |
Pharmacology for CETIRIZINE HYDROCHLORIDE HIVES
| Drug Class | Histamine-1 Receptor Antagonist |
| Mechanism of Action | Histamine H1 Receptor Antagonists |
